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Clinical Predictors of Response to Depression Treatment in Persons with Epilepsy
Juliana Hager, Frank G. Gilliam, MD, MPH
Abstract:
Background
The literature on predictors of response to treatment of depression for persons with epilepsy is
limited. This study examined predictors of response to treatment of major depression disorder
(MDD) by cognitive behavioral therapy (CBT) or Sertraline in Epilepsy patients.
Methods:
In the original two-site comparative effectiveness trial, 140 adult outpatients with active epilepsy
and current major depressive disorder were randomly assigned to either sertraline (at a dose
starting at 50 mg per day, titrating as needed at two-week intervals up to 200 mg per day) or
weekly cognitive behavior therapy (CBT) for 16 weeks . The primary outcome measure was the
depression module of the MINI-International Neuropsychiatric Interview (M.I.N.I.). Secondary
outcomes included the Quality of Life in Epilepsy Inventory (QOLIE)-89, seizure rates, the
Adverse Events Profile (AEP), the Beck Depression Inventory II, and the M.I.N.I. Suicide Risk
Module. A logistic regression model analysis was performed on patient clinical, psychosocial,
and demographic variables previously identified as significantly significant in an attempt to
develop a predictive model for positive MDD treatment response in persons with Epilepsy.
Results:
The variable that was predictive of MDD treatment response was the severity of the depression
at baseline according to the Centers for Epidemiological Studies- Depression (CES-D) with a
more severe baseline depression showing a lower response rate.
Conclusion:
The more severe MDD at baseline in epilepsy patients was shown to be predictive of a lower
response to depression treatment with Sertraline or CBT in persons with Epilepsy.
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Introduction:
The clinical usefulness of predictors of response to treatment is obvious. Several studies have
investigated the clinical predictors of response to acute treatment of major depressive disorder .
There is no literature on the predictors of response to MDD treatment in persons with Epilepsy.
Epilepsy affects over 1% of the US population . Depression is the most common comorbid
disorder in epilepsy, and is associated with reduced quality of life, increased health-care
utilization, and greater mortality . A recent population-based study found that suicide is
increased 32-fold in persons with a history of both epilepsy and affective disorder compared to
the general population .
A randomized control trial of Sertraline and Cognitive Behavioral Therapy was done for persons
with Epilepsy and MDD. Depression improved following sertraline or CBT, with most subjects
in both groups achieving remission. Despite the complex psychosocial disability associated with
recurrent seizures, improving depression can have a substantial benefit to quality of life. This
study examines predictors of response to depression treatment with persons with epilepsy. The
data comes from the RCT trial of Sertraline and CBT for depression in Epilepsy, two-site
comparative effectiveness trial .
Material and Methods:
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In the original study, a 16-week intervention intended to eliminate depression was administered.
The study randomly assigned 140 adult outpatients with epilepsy and current major depressive

disorder to sertraline or weekly CBT for 16 weeks. Each subject’s physician continued epilepsy
management. Either sertraline or CBT was the treatment for depression. Sertraline was initiated
at 50mg per day and increased by 50mg at 2-week intervals as needed for a CES-D score > 14,
up to a maximum dose of 200 mg per day. Cognitive behavior therapy was administered by a
licensed therapist using standardized, manual-based Beck guidelines in a 1-hour session each
week. The therapist completed a weekly written assessment to document the components of CBT
utilized in each session. Participants were encouraged to attend every session in person, but a
minority of the sessions could be performed by telephone in consideration of transportation
limitations of many persons with epilepsy. If subjects stopped assigned treatment but did not
withdraw consent to participate, the protocol allowed outcomes assessments to be continued for
the entire 16-week study period.
Baseline assessments were made prior to randomization. Subjects were re-evaluated with each
outcome measure during a research clinic visit every 4 weeks. A telephone assessment for
depression severity (Beck Depression Inventory [BDI] and CES-D), seizures, and treatment side
effects was obtained at the 2-week interval between clinic visits. A detailed description of the
rationale and design of the overall project may be found in Gilliam FG et al .
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The statistical analysis of the data was carried out with the statistical package SPSS Version 27
in two steps. Variables were selected for inclusion of the analysis based on their known
association with depression and were assessed at baseline. These included gender, age, years of
education, baseline depression severity scores (CES-D), baseline QILIE-89 score, experiencing a
generalized tonic-clonic seizure ever, ethnicity, driving status, marital status, employment status,
epilepsy foundation of America Concerns Index (EFA) score, and the social support and social
isolation subscale scores measured on the QOLIE-89 at baseline.
First, any possible association between each independent variable was explored in univariate
analysis; for two quantitative variables a chi-squared test was used, while a t-test for differences
between means was used for continuous variables. Finally, to estimate the effect of each
independent variable on the depression remission, logistic regression models were run. The
dichotomous variable in the logistic regression model is MDD active or in remission at sixteen
weeks (based on the MINI score). All the hypotheses were rejected at an alpha level of .05.
Results:
A total of 140 participants were enrolled and randomly assigned to either the sertraline or CBT
treatment groups. At enrollment the mean age of the cohort was 39 years, seventy-seven
subjects were women. No differences were found between treatment groups with respect to
baseline number of seizure medications, BDI scores, CES-D scores, AEP scores, or QOLIE-89
scores. As a comparative effectiveness trial, the protocol allowed follow up after stopping
assigned treatment, so that 117 (83.6%) participants completed assessments at week 16.
Of the 117 subjects that completed the final assessment, the mean BDI scores at baseline and
week 16 for the sertraline group (n=59) were 24.2 (s.d 8.4) and 12.3 (s.d. 9.9), and for the CBT
group (n=58) were 26.9 (s.d. 10.5) and 12.8 (s.d. 11.9). Of the 96 subjects that completed the
MINI at week 16, 38 of the 48 (79.2%; 95%CI±11.5) in the sertraline group and 41 of 48
(85.4%; 95% CI±10.0) in the CBT group were in remission from major depression (between

group chi-square=0.64; p =0.42).For a detailed description of the original patient group, see the
original study (Guilliam FG).
The the primary univariate analysis showed that the baseline CES-D (p-value< .0001), and
ethnicity (p-value<.00001 ) were statistically significant variables (Tables 1&2)
We included in the logistic regression the variables that were found to be statistically significant
on univariate analysis. The logistic regression model showed that the baseline severity of
depression based on the CES-D score was a significant clinical predictor of response to
depression treatment in Epilepsy persons (p< .035 with a OR 1.062) (Table 3). The more severe
the MDD was at baseline, the higher the CES-D, the less likely the patient with Epilepsy was to
respond to depression treatment.
Table 1: Relationship of continuous
variables at baseline and MDD Remission
based on the MINI score at 16 weeks

Depression Remission at 16 Depression Active
Weeks
at 16 Weeks

P

Education Years (Mean)

14.37

13.96

0.50

Age (Mean)

40.68

37.08

0.17

CES-D (Mean)

29.09

36.71

0.00*

QOLIE-89 (Mean)

56.12

57.71

0.70

EFA (Mean)

58.70

66.21

0.07

Discussion:
In this study we aimed to evaluate the predictive variables to depression treatment that can be
obtained in clinical evaluation of persons with Epilepsy. The ethnicity variable, while significant
in the univariate analysis was not significant in the logistic regression. Only four of the patients
were of Hispanic or Latino origin, so these results cannot be representative of the population. A
more representative population of a Hispanic population should be further studied. A further
analysis of variables in each treatment group (Sertraline vs CBT) could yield more specific
data.
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